HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”

BACKGROUND: Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low‐density lipoprotein cholesterol (LDL‐C) and improve outcomes in the general population. HIV‐infected individuals are at increased risk for cardiovascular events and have high rates of dyslipidemia and hepatitis C viru...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohli, Payal, Ganz, Peter, Ma, Yifei, Scherzer, Rebecca, Hur, Sophia, Weigel, Bernard, Grunfeld, Carl, Deeks, Steven, Wasserman, Scott, Scott, Rob, Hsue, Priscilla Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889164/
https://www.ncbi.nlm.nih.gov/pubmed/27130349
http://dx.doi.org/10.1161/JAHA.115.002683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889164/
https://www.ncbi.nlm.nih.gov/pubmed/27130349
http://dx.doi.org/10.1161/JAHA.115.002683

Ejemplares similares